One Health Initiative Webinar Series: Part 1

One Health -- Embracing In Silico Models for Therapeutic Needs in Humans and Animals


Broadcast Date: Thursday, July 28th | 11:00 a.m. - 12:00 p.m. Eastern

Click to view the recording!

The One Health Initiative is a worldwide strategy for expanding interdisciplinary collaborations and communications in all aspects of health care for humans, animals and the environment. Whether dealing with the development of shared diseases among humans and animal species (physiological diseases such as those involving the cardiovascular system or cancer) or efforts to combat infections and drug resistance, tools are needed to optimize the efficiency with which we utilize existing information to support therapeutic drug development.  Such tools can likewise be used to predict the potential absorption of substances resulting from their unintended environmental exposures. It is this perspective that provided the impetus for this webinar series where we explore the meaning of the One Health initiative and how we can best utilize existing information to support the development of therapeutic formulations for use in humans and veterinary species, to adjust dosages or dosage forms to meet emergency needs that may arise around the globe, or how to explore exposure risks that may occur in the presence of environmental toxins.

The first lecture in this series will provide an overview of the One Health Initiative and of the application of in silico (mechanistic) models for supporting therapeutic product development across a diverse patient population (human or veterinary).

What attendees will take away:

  • The One Health Initiative provides a unique opportunity to leverage knowledge and research across disciplines in order to develop therapeutic options that address the emerging health issues impacting human and animal health.
  • Computer-based mechanistic models are an invaluable tool for facilitating an integration of information derived from in vivo and in vitro sources, thereby optimizing the efficiency of efforts to address the evolving and global therapeutic needs.
  • This series of three webinars will showcase the strengths and potential application of these tools for use by researchers involved with understanding the biopharmaceutics, pharmacokinetics and pharmacokinetic/pharmacodynamics relationships of pharmaceutical drugs and drugs in formulations (including those scientists from academia, industry, and government), physicians, veterinarians, and environmental scientists.

Who should attend this webinar:

Individuals involved with the development and use of therapeutic products from the perspective of biopharmaceutics, pharmacokinetics, dose-exposure-response relationships, and interspecies extrapolations (including researchers from academia, industry, and government); physicians; veterinarians; students (human or veterinary medicine, university); environmental scientists.

About the Speakers


Marilyn Martinez, US FDA/Center for Veterinary Medicine, Rockville, MD
Marilyn is a Senior Biomedical Research Scientist for the US Food and Drug Administration, Center for Veterinary Medicine (CVM). In addition to her responsibilities at the CVM, her activities and include her role as a voting member of the Veterinary Antimicrobial Susceptibility Testing Subcommittee of the Clinical Laboratory Standards Institute, chair of the Veterinary International Conference on Harmonization bioequivalence expert working group, Adjunct Professor in the College of Veterinary Medicine, North Carolina State University, Federal Liaison to OrBITO, member of the Editorial Board of the Journal of Veterinary Pharmacology and Therapeutics, and Associate Editor of the AAPS Journal. She is the recipient of the 2015 Lloyd Davis Lifetime Achievement Award, and was elected as Fellow of the American Association of Pharmaceutical Scientists and the Controlled Release Society. She received her Ph.D. from the Department of Physiology and Biophysics, Georgetown University School of Medicine.


Dr. Bernadette Dunham (D.V.M, Ph.D.), Milken Institute School of Public Health, George Washington University, Washington D.C.
Dr. Bernadette Dunham is currently a Visiting Professor with the Milken Institute School of Public Health at George Washington University where her focus is on One Health issues. Dr. Dunham served as Director of the Center for Veterinary Medicine (CVM) at the U.S. Food and Drug Administration (FDA) from 2008-2016. Dr. Dunham received the degree of Doctor of Veterinary Medicine (D.V.M.) from the Ontario Veterinary College at the University of Guelph, and a Ph.D. in cardiovascular physiology from Boston University.



Dr. Xinyuan (Susie) Zhang (Ph.D.), US FDA/Center for Drug Evaluation and Research (CDER)/Office of Generic Drugs (OGD)/Office of Research and Standards (ORS)/Division of Quantitative Methods and Modeling (DQMM), Silver Spring, MD
Dr. Xinyuan (Susie) Zhang is currently a Scientific Lead in the Division of Quantitative Methods and Modeling (DQMM)/Office of Research and Standards (ORS)/Office of Generic Drugs (OGD)/ Center for Drug Evaluation and Research (CDER). Her main responsibility is implementing modeling and simulation in various generic drug review processes, such as Abbreviated New Drug Application (ANDA) review, response to consult request, response to controlled correspondences, and bioequivalence guidance development. She received her Ph.D. from the Department of Pharmaceutical Sciences, the University of Michigan, Ann Arbor.
© Copyright Controlled Release Society  | Contact Us - Report a Bad Link